Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644002 | 0.94 | TSHR (0.46) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL19454696 | 0.92 | TSHR (0.43) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL14398801 | 0.83 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL3123165 | 0.82 | TSHR (0.44) | TSHRALDH1A1TAS1R3TAS1R1PLA2G2C | |
| SCHEMBL25340146 | 0.81 | TSHR (0.57) | TSHRALDH1A1PLA2G2C | |
| SCHEMBL19302134 | 0.79 | TSHR (0.39) | TSHRALDH1A1SIGMAR1TAS1R3TAS1R1 | |
| SCHEMBL3116791 | 0.79 | TSHR (0.48) | TSHRALDH1A1TAS1R3TAS1R1PLA2G2C | |
| SCHEMBL5349650 | 0.77 | SIGMAR1 (0.43) | TSHRALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL23011370 | 0.77 | TSHR (0.40) | TSHRALDH1A1TAS1R3TAS1R1PLA2G2C | |
| SCHEMBL12662790 | 0.76 | TSHR (0.43) | TSHRALDH1A1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | METRO INTERNATIONAL BIOTECH, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | METROBIOTECH, LLC | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147227-A1 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND THEIR USES | NAMPT, NNT, NQO1 | TSHR 3861/4885ALDH1A1 1078/4885SIGMAR1 4800/4885 |
| US-10548913-B2 | Nicotinamide mononucleotide derivatives and their uses | NAMPT, NNT, NQO1 | TSHR 3861/4885ALDH1A1 1078/4885SIGMAR1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.